# Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

> **NCT03630731** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 32 (estimated)

## Conditions studied

- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

## Interventions

- **DRUG:** chidamide

## Key facts

- **NCT ID:** NCT03630731
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2018-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03630731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03630731, "Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03630731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*